Kimberly-Clark InteguSeal microbial sealant wins medical design by lqh68203

VIEWS: 30 PAGES: 1

									6 September 15 2008 EACTS Daily News



        Surgery, Medical School, Kiel, Germany; University
        of Wisconsin Department of Cardiothoracic Surgery,
                                                              Kimberly-Clark InteguSeal* microbial sealant                                                                                          gical equipment, instruments and sup-
                                                                                                                                                                                                    plies category of the MDEA competi-

                                                              wins medical design excellence award
        Medical School, Madison, Wisconsin, USA                                                                                                                                                     tion.
Invited Discussant: T Walther, Leipzig                                                                                                                                                                 “We are honoured and delighted to
10:15 Mechanisms of failure of aortic valve repair: an                                                                                                                                              be recognized by the MDEA judges for


                                                              I
        intraoperative transoesophageal                          nteguSeal*, the innovative microbial                                                   vative use of materials, user-related       InteguSeal* Microbial Sealant,” said
        echocardiographic study                                  sealant from Kimberly-Clark Health                                                     functions that improve health care          Kimberly-Clark Vice President of Global
        J-B Le Polain de Waroux; A-C Pouleur; A Pasquet;         Care, has been singled out for a pres-                                                 delivery and change traditional med-        Sales and Marketing John Amat. “This
        M Van Dyck; P Noirhomme; J-L J Vanoverschelde;        tigious medical design excellence                                                         ical attitudes or practices, features       award recognizes the important work
        G El Khoury
                                                              award.                                                                                    that provide enhanced benefits to the       that medical device companies are
        Cliniques Universitaires, St Luc Universite
                                                                  Designed to reduce the risk of skin                                                   patient and the ability of the product      doing to advance the design and func-
        Catholique de Louvain, Brussels, Belgium
Invited Discussant: M J Antunes, Coimbra                      flora contamination throughout a surgi-                                                   development team to overcome                tionality of products that contribute to
                                                              cal procedure,                                                                            design and engineering challenges so        improved patient outcomes and aid
Auditorium 3&4 Session 6
                                                                  InteguSeal* Microbial Sealant             Excellence Awards (MDEA) competi-           the product meets its clinical objec-       medical professionals on the front lines
Thymus
Chairmen: L Spaggiari, Milan                                  (www.integuseal.com) uses a propri-           tion is organized and presented by          tives.                                      of delivering care.”
              P Van Schil, Antwerp                            etary formulation to seal and immobi-         Canon Communications LLC (Los                  A comprehensive review of the               The 2008 Medical Design Excellence
09:30 Clinical outcomes of video-assisted                     lize pathogens to help protect against        Angeles) and is the only awards pro-        entries was performed by a multidiscipli-   Award winners were honoured at a
      thoracoscopic surgery (vats) for thymomas               migration into an incision. To date,          gram that exclusively recognizes con-       nary panel of third-party jurors with       ceremony during the Medical Design &
      A Thirugnanam 1; J L Soon 2                             InteguSeal* has been used in more             tributions and advances in the design       expertise in biomedical engineering,        Manufacturing (MD&M) East
      1 National Cancer Center, Singapore;                    than 150,000 applications during surgi-       of medical products. Entries are evalu-     human factors, industrial design, medi-     Conference and Exposition, June 3–5,
      2 National Heart Center, Singapore                      cal procedures across the world.              ated on the basis of their design and       cine and diagnostics. InteguSeal*           2008, at New York City’s Jacob K. Javits
09:42 Plasmapheresis before thymectomy in                         The US-based 2008 Medical Design          engineering features, including inno-       received the top gold award in the sur-     Convention Center.
      myasthenia gravis: routine vs. Selective
      protocols
      K Al-Kattan1; H El-Bawab1; W Hajjar 2; M Rafay1; A
      Bamousa1; A Khalil1
                                                              Does pretransplant LVAD support improve                                                                                pared to direct transplantation in patients with ele-
                                                                                                                                                                                     vated PVR.
      1 King Faisal Specialist Hospital and Research
      Center, Riyadh, Saudi Arabia;                           results after heart transplantation in                                                                                    All heart transplant recipients at Sahlgrenska
                                                                                                                                                                                     University Hospital, Gothenburg, during the period
      2 King Khalid University Hospital, Riyadh, Saudi
      Arabia                                                  patients with elevated PVR?                                                                                            1988-2007 with pretransplant PHT were divided into
                                                                                                                                                                                     two groups. Group 1 were patients without LVAD
09:54 Association of thymoma and myasthenia gravis:


                                                              O
      oncological and neurological results of surgical                 rthothopic heart transplantation is the gold        of death after cardiac                                    treatment (n=58) and group 2 patients treated with
      treatment                                                        standard for patients with terminal heart fail-     transplantation and PVR                                   LVAD prior to transplant (n=11).
      M Lucchi; F Melfi; P Dini; F Davini; L Duranti;                  ure. Progress in the underlying disease leads to    < 5 WU is regarded as a                                      Group 1 had a mean pretransplant PVR of 3.2 ±
      A Viti; A Mussi                                         backward failure and changes in the pulmonary circu-         contraindication for heart                                0.7. Group 2 had a mean pretransplant PVR of 3.2 ±
      Azienda Ospedaliera Universitaria Pisana, Pisa, Italy   lation, eventually leading to decreased right ventricu-      transplantation. Recently                                 0.9 that was reduced to 2.1 ± 0.6 after LVAD treat-
10:06 Early masaoka stage and complete resection is           lar function. Remodelling of the pulmonary vascula-          it has been shown that                                    ment. Two cases of acute right heart failure after
      important for the prognosis of thymic                   ture occurs quickly, at first reversible, but at some        circulatory support with a                                transplantation required mechanical support in group
      carcinoma: from the 20-year experience of a             point becoming irreversible, resulting in a fixed pul-       left ventricular assist                                   1. None of the patients in group 2 developed periop-
      single institution                                      monary vascular resistance (PVR). However, an                device (LVAD) can reduce                                  erative right heart failure requiring mechanical sup-
      C Y Lee; I K Park; M K Bae; K Chung                     absolute cut-off value of PVR does not exist. The right      the resistance in the pul-                                port. The incidence of other perioperative complica-
      Department of Thoracic and Cardiovascular Surgery
                                                              ventricle of the donor heart tolerates increased PVR         monary vasculature. It                                    tions was comparable between the two groups. Four-
      Yonsei University College of Medicine, Seoul, Korea
                                                              poorly, resulting in acute perioperative right-sided fail-   has furthermore been                                      year survival in group 1 and 2 was 70% and 63 %,
      (South)
                                                              ure, which can be difficult to manage pharmacologi-          shown that transplanted                    Lars Wiklund   respectively.
10:18 Long-term outcome of extended thoracoscopic
      thymectomy for nonthymomatous myasthenia                cally. After heart transplantation in patients with ele-     patients with elevated PVR                                   Pretransplant LVAD treatment reduced the pul-
      gravis                                                  vated PVR, the majority of survivors will normalize          pre-treated with LVAD have as good a survival as          monary pressure in heart transplant recipients with
      E Pompeo; F Tacconi; R Massa;                           their PVR which questions the irreversibility of elevat-     patients with normal PVR. After those important find-     PHT but there was no statistically significant differ-
      G Bernardi; T C Mineo                                   ed resistance.                                               ings we now consider pretransplant LVAD implantation      ence in short-term survival in patients treated with or
      Department of Thoracic Surgery, Policlinico Tor            Pulmonary hypertension (PHT) is a risk factor for         to be indicated rather than contraindicated in patients   without LVAD. The relatively good results in patients
      Vergata University, Rome, Italy                         early and late death after heart transplantation. There is   with elevated PVR.                                        with elevated PVR and no prior LVAD treatment can
Auditorium 2 Session 7                                        a consensus that PVR < 2.5 Wood units (WU) and                  The purpose of this study was to determine the         be accredited early and powerful pharmaceutical
                                                              resistant to pharmacologic dilatation increases the risk     outcome of pretransplant treatment with LVAD com-         treatment of right heart failure.

								
To top